Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 1:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 27,803 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo and sham treatment Clear all
Terminated Phase 1Phase 2 Interventional Results available

rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease

NCT02702518
View directory record Official record
Conditions
Ocular Graft vs Host Disease, Dry Eye
Interventions
rhDNase I, Vehicle
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 26, 2026, 1:10 PM EDT
Terminated Phase 3 Interventional

Inhaled Nitric Oxide in Prevention/Treatment of Ischemia-Reperfusion Lung Injury Related to Lung Transplantation

NCT00060450
View directory record Official record
Conditions
Ischemia-Reperfusion Injury
Interventions
nitric oxide for inhalation, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 26, 2026, 1:10 PM EDT
Not listed Not applicable Interventional

Safety and Efficacy Study of Deep Transcranial Magnetic Stimulation in Bipolar Depression

NCT01566591
View directory record Official record
Conditions
Bipolar Depression
Interventions
Deep TMS Treatment, Sham Treatment
Device
Lead sponsor
Brainsway
Industry
Eligibility
22 Years to 68 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
9
States / cities
Juno Beach, Florida • Palm Beach, Florida • Royal Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 26, 2026, 1:10 PM EDT
Recruiting Phase 2 Interventional

Nicotinamide Mononucleotide in Patients Undergoing Cardiac Surgery

NCT07013591
View directory record Official record
Conditions
Cardiac Surgery
Interventions
MIB-626, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 26, 2026, 1:10 PM EDT
Completed Phase 2 Interventional

Interferon-Alpha for Diabetes Mellitus Type 1

NCT00024518
View directory record Official record
Conditions
Insulin-Dependent Diabetes Mellitus
Interventions
30,000 units hrINF-alpha, 5,000 hrINF-alpha, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
3 Years to 25 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
5
States / cities
Bethesda, Maryland • Saint Paul, Minnesota • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 26, 2026, 1:10 PM EDT
Completed Phase 3 Interventional Results available

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

NCT01196091
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
Interventions
LY2127399, Placebo every 2 weeks, Placebo every 4 weeks, Standard of Care
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
88
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 26, 2026, 1:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects

NCT04019574
View directory record Official record
Conditions
Healthy
Interventions
CR845 0.5 mcg/kg IV, CR845 3 mcg/kg IV, Moxifloxacin 400 mg Oral Tablet, Placebo
Drug · Other
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 26, 2026, 1:10 PM EDT
Terminated Phase 2 Interventional Results available

A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain

NCT02192190
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
LY2951742, Placebo- oral, Placebo - SC, Celecoxib
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years to 75 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
38
States / cities
Birmingham, Alabama • Anaheim, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 26, 2026, 1:10 PM EDT
Completed Phase 2 Interventional Results available

Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury

NCT00597818
View directory record Official record
Conditions
NSAID-induced Gastroduodenal Injury, Ulcers, Rheumatoid Arthritis, Osteoarthritis
Interventions
Cobiprostone, Placebo, Non-steroidal anti-inflammatory drug
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
40 Years to 70 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Phoenix, Arizona • Chula Vista, California • Loma Linda, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 26, 2026, 1:10 PM EDT
Terminated Phase 2 Interventional Results available

Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19

NCT04400890
View directory record Official record
Conditions
COVID-19
Interventions
Resveratrol, Vitamin D3
Drug · Dietary Supplement
Lead sponsor
Marvin McCreary, MD
Other
Eligibility
45 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 26, 2026, 1:10 PM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility

NCT01902290
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Brodalumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
73
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 26, 2026, 1:10 PM EDT
Completed Phase 3 Interventional Results available

Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.

NCT03108482
View directory record Official record
Conditions
Acute Post-surgical Pain
Interventions
Co-crystal E-58425 (Tramadol/Celecoxib), Tramadol (Ultram®), Celecoxib (Celebrex®), Placebo
Drug
Lead sponsor
Esteve Pharmaceuticals, S.A.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 26, 2026, 1:10 PM EDT
Recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH

NCT07625280
View directory record Official record
Conditions
Narcolepsy, Idiopathic Hypersomnia
Interventions
Xywav, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Irvine, California • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 26, 2026, 1:10 PM EDT
Completed Phase 4 Interventional Results available

A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents

NCT02714062
View directory record Official record
Conditions
Pediatric Obesity, Childhood Obesity
Interventions
Placebo, VI-0521 Mid Dose, VI-0521 Top Dose
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Baton Rouge, Louisiana • Marrero, Louisiana • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 26, 2026, 1:10 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease

NCT06773962
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
TB006, Placebo
Drug
Lead sponsor
TrueBinding, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Aliso Viejo, California • Palo Alto, California • Englewood, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 26, 2026, 1:10 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY2189102 in Patients With Type 2 Diabetes

NCT00942188
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
LY2189102, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
18
States / cities
Mobile, Alabama • Anaheim, California • Chula Vista, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 26, 2026, 1:10 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Spry Belt for Improving Bone Quality

NCT03986203
View directory record Official record
Conditions
Osteopenia
Interventions
Spry Belt
Device
Lead sponsor
Theranova, L.L.C.
Industry
Eligibility
50 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 26, 2026, 1:10 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee

NCT00504127
View directory record Official record
Conditions
Osteoarthritis
Interventions
Naproxcinod 375 mg bid, Naproxcinod 750 mg bid, Naproxen 500 mg bid, placebo
Drug
Lead sponsor
NicOx
Industry
Eligibility
40 Years and older
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
73
States / cities
Chandler, Arizona • Tempe, Arizona • Tucson, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2011 · Synced Oct 26, 2026, 1:10 PM EDT
Completed Not applicable Interventional Results available

Percutaneous Peripheral Nerve Stimulation (Neuromodulation) for Postoperative Analgesia

NCT02898103
View directory record Official record
Conditions
Postoperative Pain
Interventions
Percutaneous peripheral nerve stimulation, Sham stimulation
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 26, 2026, 1:10 PM EDT
Recruiting Phase 3 Interventional

A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder

NCT07767903
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
SEP-363856, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Redlands, California • Orlando, Florida • Watertown, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 26, 2026, 1:10 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

NCT01844986
View directory record Official record
Conditions
Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation, Complete Response, Partial Response, First Line Platinum Chemotherapy
Interventions
Olaparib 300mg tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
81
States / cities
Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 26, 2026, 1:10 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Anti-IgE in Non-Allergic Asthma

NCT00162773
View directory record Official record
Conditions
Asthma
Interventions
omalizumab, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Oct 26, 2026, 1:10 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Lutein, Zeaxathin, and Fish Oil Supplementation

NCT06489873
View directory record Official record
Conditions
Cognitive Performance, Age-Related Macular Degeneration, Bone Loss
Interventions
Active Comparator (Lutein, zeaxanthin, and fish oil supplement (LZF), Placebo Comparator
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 26, 2026, 1:10 PM EDT
Active, not recruiting Phase 3 Interventional

Nipocalimab in Moderate to Severe Sjogren's Disease

NCT06741969
View directory record Official record
Conditions
Sjogrens Syndrome
Interventions
Nipocalimab, Placebo, Standard of care treatment
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
43
States / cities
Chula Vista, California • Fullerton, California • La Palma, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 26, 2026, 1:10 PM EDT